Home/Pipeline/Non-invasive Neuromodulation for Parkinson's Disease

Non-invasive Neuromodulation for Parkinson's Disease

Parkinson's Disease

Pre-clinicalActive

Key Facts

Indication

Parkinson's Disease

Phase

Pre-clinical

Status

Active

Company

Synergic Medical Technologies

About Synergic Medical Technologies

Synergic Medical Technologies is pioneering a non-invasive neuromodulation platform targeting the dysfunctional brain networks underlying Parkinson's disease. Founded in 2017, the company is advancing a therapeutic device that has secured FDA Breakthrough Device Designation, indicating significant potential to address an unmet medical need. Operating as a pre-revenue, private entity, Synergic is positioned in the high-growth neurotherapy segment of the medical device sector. Its approach aims to offer a drug-free, potentially home-based alternative to existing invasive treatments like deep brain stimulation.

View full company profile

Therapeutic Areas

Parkinson's Disease

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active